CFM
BBIO icon

Crawford Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Crawford Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Sell
3,500
-8,000
-70% -$580K 0.05% 162
2025
Q4 		$880K Hold
11,500
– – 0.12% 140
2025
Q3 		$597K Sell
11,500
-12,000
-51% -$585K 0.1% 161
2025
Q2 		$1.01M Sell
23,500
-23,500
-50% -$855K 0.19% 117
2025
Q1 		$1.62M Sell
47,000
-18,500
-28% -$624K 0.39% 75
2024
Q4 		$1.8M Buy
65,500
+42,000
+179% +$1.09M 0.31% 97
2024
Q3 		$598K Buy
23,500
+2,900
+14% +$76.1K 0.13% 135
2024
Q2 		$522K Sell
20,600
-7,200
-26% -$197K 0.13% 129
2024
Q1 		$860K Buy
+27,800
New +$945K 0.21% 110

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return